All In Biotech

Drug Trial Radar · NCT06987643

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Jun 20, 2025

Primary completion

Sep 23, 2026

Study completion Oct 6, 2026

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
CervoMed, Inc.
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.

Conditions

  • Moderate to Severe Acute Ischaemic Stroke
  • Ischaemic Stroke

Interventions

  • NeflamapimodDrug

    Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules

  • PlaceboDrug

    Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Week 12 in Fugl-Meyer Assessment of Motor Recovery after Stroke (FMMS) motor score (upper and lower) and total scoreTime frame: From enrollment until the end of treatment at 12 weeks
  2. Change from baseline to Week 12 in the Timed Up and Go Test (TUG)Time frame: From enrollment until the end of treatment at 12 weeks
  3. Change from baseline to Week 12 in National Institutes of Health Stroke Scale (NIHSS) motor scoreTime frame: From enrollment until the end of treatment at 12 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Western Health- Sunshine Hospital

    St Albans, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.